What should we do after the failure of a first anti-TNF?

Golimumab effectively reduces the signs and symptoms of active rheumatoid arthritis in patients who have previously failed treatment with at least one tumor necrosis factor inhibitor. Is it now time to develop strategies for sequential drug administration?